SAN DIEGO, August 5, 2019 – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, will present clinical research data at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), September 16-20 in Barcelona, Spain.
Poster presentations co-authored by ProSciento scientists include:
- Effects of efpeglenatide on weight, BMI, and waist circumference in those with obesity without diabetes stratified by baseline characteristics: subanalysis of BALANCE 205
Abstract # 763
Session: Novel drug therapies: The future of incretin-based therapies
» Link to Abstract
- Relationship between glycaemic control and weight loss with once-weekly efpeglenatide in uncontrolled type 2 diabetes: a subanalysis of EXCEED 203
Abstract # 764
Session: The future of incretin-based therapies
» Link to Abstract
- Efficacy of efpeglenatide in patients with obesity and prediabetes: a subanalysis of the BALANCE 205 study
Abstract # 765
Session: The future of incretin-based therapies
» Link to Abstract
To inquire about a meeting with a member of ProSciento’s scientific or executive teams during the EASD Annual Meeting or the AASLD Liver Meeting in November, please click here or email us at bd@prosciento.com.
About ProSciento, Inc.
ProSciento is a highly specialized clinical research organization (CRO)
exclusively focused on NASH, diabetes, obesity and related metabolic diseases.
ProSciento works with biopharma companies worldwide to support their outsourced
clinical research needs with comprehensive and customized services for
multinational, early development clinical trial programs. Founded in 2003,
ProSciento has conducted more than 280 clinical projects for diabetes, NASH and
obesity and supported the development of many approved metabolic drugs and
devices on the market globally. For more information, please visit www.prosciento.com.
For business development inquiries, please contact:
bd@prosciento.com
For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
abby.devine@prosciento.com
For clinical trial enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com
